Breakthrough Alzheimer's Drugs 'Unlikely to Benefit Patients', Report Suggests Amidst Controversy
An influential analysis has concluded that recently heralded Alzheimer's drugs, despite their significant cost and initial promise, are unlikely to provide substantial benefit to patients. Researchers behind the report assert that the drugs' impact on cognitive decline is 'well below' the threshold required to make a tangible difference in the daily lives of individuals living with dementia.
Controversy and Backlash
This assessment has, however, provoked a fierce response from other esteemed scientists. Critics argue that the report is fundamentally flawed, primarily due to its methodology of grouping various amyloid-clearing drugs, including older experimental treatments, with newer ones that have demonstrated a modest but discernible effect on slowing cognitive decline.
Professor Edo Richard, a neurologist and co-author of the report, advises patients that they would 'probably not benefit' from these drugs, citing their limited efficacy and the 'burdensome' nature of their administration. He stressed the importance of honesty with patients to avoid 'giving false hope'.
The Science and the Cost
The drugs, such as donanemab and lecanemab, work by deploying engineered antibodies to clear beta amyloid, a sticky protein that accumulates in the brain in Alzheimer's disease. While trials have shown these drugs can slow the pace of cognitive decline – a landmark achievement – the new analysis, conducted by the Cochrane Collaboration across 17 studies involving over 20,000 volunteers, concludes this slowing is insufficient to constitute a meaningful difference for patients.
Furthermore, these treatments carry risks of brain swelling and bleeding, require administration every two to four weeks, and come with a prohibitive private cost of approximately £90,000 for an 18-month course in the UK. They are currently not funded by the National Health Service (NHS), with the National Institute for Health and Care Excellence (NICE) reviewing the evidence once again.
Professor Robert Howard of University College London (UCL), a long-standing critic, described the hype around these drugs as 'unfortunate and unfair' to affected families, suggesting it has raised 'false hopes'. Conversely, Professor Bart De Strooper from the UK Dementia Research Institute at UCL stated the review 'does not clarify the evidence, it blurs it', highlighting the 'fundamental flaw' in its approach.
Dr Richard Oakley from the Alzheimer's Society urged for a nuanced interpretation of the review, cautioning against undermining 'decades of pioneering scientific study'.
